How should a patient with chronic kidney disease stage 3b (estimated glomerular filtration rate 32 mL/min/1.73 m²) be managed?

Management of CKD Stage 3b (eGFR 32 mL/min/1.73 m²)

Start an SGLT2 inhibitor immediately, as this is now a cornerstone therapy for all CKD patients with eGFR ≥20 mL/min/1.73 m² regardless of diabetes status, and continue it even if eGFR falls below 20. 1

Core Pharmacologic Management

First-Line Therapy: SGLT2 Inhibitors

The 2024 KDIGO guidelines provide the strongest recommendation (1A) for SGLT2 inhibitors in your patient with eGFR 32:

• If albuminuria ≥200 mg/g or heart failure present: Strong 1A recommendation to start SGLT2i 1
• If albuminuria <200 mg/g: Still recommended with 2B strength 1
• Critical practice point: Continue SGLT2i even if eGFR drops below 20 unless dialysis is initiated 1
• The reversible eGFR dip after initiation is expected and not a reason to stop 1
• Withhold only during prolonged fasting, surgery, or critical illness (ketosis risk) 1

Recent evidence from CREDENCE confirms that continuing canagliflozin when eGFR falls <20 maintains kidney and cardiovascular benefits without additional safety concerns 2.

RAS Inhibition (ACEi or ARB)

Continue or initiate ACEi/ARB even at eGFR 32 - this is explicitly stated in KDIGO 2024 1:

• If albuminuria present: Strong recommendation regardless of diabetes status 1
• Use the highest tolerated dose proven in trials 1
• Key safety monitoring: Check creatinine and potassium 2-4 weeks after initiation or dose increase 1
• Do NOT stop unless creatinine rises >30% within 4 weeks 1
• Do NOT stop just because eGFR is 32 - guidelines explicitly state to continue even when eGFR falls below 30 1
• Manage hyperkalemia with potassium-lowering measures rather than stopping the RASi 1

Nonsteroidal MRA (Finerenone)

Consider adding finerenone if the patient has diabetes, albuminuria >30 mg/g, and normal potassium despite maximized RASi 1:

• Requires eGFR >25 (your patient at 32 qualifies) 1
• Dose: 10 mg daily for eGFR 25-59 1
• Strict potassium monitoring required: Must have K+ ≤4.8 mmol/L to initiate 1
• Can be added on top of both RASi and SGLT2i 1
• Most appropriate for high-risk patients with persistent albuminuria despite other therapies 1

Essential Monitoring and Complications

Laboratory Surveillance

At eGFR 32, monitor for stage 3b CKD complications:

• Anemia: Check hemoglobin, iron studies, consider iron supplementation if deficient 3
• Mineral bone disease: Monitor calcium, phosphate, PTH, vitamin D
• Metabolic acidosis: Check serum bicarbonate
• Hyperkalemia: Especially critical when using RASi or MRA 1
• eGFR and albuminuria: Regular monitoring to assess progression risk 4

Cardiovascular Risk Reduction

CKD patients die from cardiovascular disease more often than they progress to dialysis 5:

• Statin therapy: For cardiovascular risk reduction
• Blood pressure target: Systolic <130 mmHg if tolerated (evidence shows significant improvement in outcomes) 6
• Lipid management: Target total cholesterol <4.5 mmol/L, LDL <2.5 mmol/L 6

Nephrology Referral Criteria

Your patient does NOT yet meet urgent referral criteria, but refer if any of the following develop 5:

• eGFR falls below 30 mL/min/1.73 m²
• Albuminuria ≥300 mg per 24 hours
• Rapid eGFR decline (>5 mL/min/1.73 m² per year)
• Uncontrolled hypertension despite multiple agents
• Persistent hyperkalemia or metabolic acidosis

Critical Pitfalls to Avoid

Do not stop RASi just because eGFR is 32 - this is a common error. Guidelines explicitly state to continue even below 30 1. The REVEAL-CKD study showed that proper CKD diagnosis and management reduced annual eGFR decline from 3.20 to 0.74 mL/min/1.73 m² 7.

Do not withhold SGLT2i due to eGFR concerns - the threshold is 20, not 30, and continuation below 20 is recommended 1, 2.

Do not forget albuminuria testing - only 24% of at-risk patients receive appropriate albuminuria testing, yet this drives treatment decisions 8. Measure urine albumin-to-creatinine ratio if not already done.

Avoid nephrotoxins: NSAIDs, certain antibiotics, contrast agents (use with caution and adequate hydration) 5.

Adjust medication dosing: Many drugs require dose adjustment at eGFR 32, including certain antibiotics, anticoagulants, and oral hypoglycemics 5.

Practical Algorithm

1. Measure albuminuria if not done recently
2. Start SGLT2i (dapagliflozin 10mg, empagliflozin 10mg, or canagliflozin 100mg daily)
3. Optimize RASi to maximum tolerated dose
4. If diabetic with albuminuria >30 mg/g and K+ ≤4.8: Add finerenone 10mg daily
5. Monitor K+ and creatinine 2-4 weeks after any medication change
6. Ensure statin therapy and BP control
7. Screen for CKD complications (anemia, bone disease, acidosis)
8. Recheck eGFR and albuminuria every 3-6 months to assess progression